Chromenoneindoles

Details Chromenoneindoles Chromenoneindoles

2011-06-28

2011-06-28

Wilson, James O (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S373000

Reexamination Certificate

active

07968551

ABSTRACT:
Chromenoneindole derivatives of the formula (I), in which R1, R2, R3, R, A and B are as defined in Claim1, and pharmaceutically usable prodrugs, derivatives, solvates, stereoisomers and salts thereof, exhibit particular actions on the central nervous system, in particular 5-HT reuptake-inhibiting and 5-HTx-agonistic and/or -antagonistic actions. They are distinguished by particularly high bioavailability and particularly high inhibition of 5-HT reuptake.

REFERENCES:
patent: 5532241 (1996-07-01), Bottcher et al.
patent: 6251908 (2001-06-01), Bottcher et al.
patent: 19730989 (1999-01-01), None
patent: 0648767 (1995-04-01), None
West, Anthony R., “Solid State Chemistry and its Applications”, Wiley, new York, 1988, pp. 358 & 365.
Gaster, L.M. et. al., Ann. Reports Med. Chem., 1998, vol. 33, pp. 21-30.
Ann M. Mortimer, Expert Opinion on Investigational Drugs, 2004, vol. 13, No. 4, pp. 315-329.
Newman et. al.; Drug Discovery Today, 2003, 8(19) p. 898.
Chawla et. al.; Current Research & Information on Pharmaceutical Science, 2004, 5(1), p. 9.
Vippagunta et. al. Advanced Drug Delivery Reviews 48 (2001) 3-26.
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface.
Borisy, et. al., Proceedings of the National Acadamy of Sciences of the United States of America, 100(13) 7977-7982.
Wolff et. al., “Burger's Medicinal Chemistry and Drug Discovery,” 5th Ed. Part 1, pp. 975-977 (1995).
Banker, et. al., Modern Pharmaceuticals, (1996) p. 596.
http://www.umm.edu/patiented/articles/what—causes—eating—disorders—000049—3.htm, last accessed Feb. 16, 2010.
http://www.wrongdiagnosis.com/s/sexual—dysfunction/causes.htm, last accessed Feb. 16, 2010.
http://en.wikipedia.org/wiki/Brain—trauma, last accessed on Jun. 10, 2010.
http://en.wikipedia.org/wiki/Learning—disorders, last accessed on Jun. 10, 2010.
http://en.wikipedia.org/wiki/memory—disorder, last accessed on Jun. 10, 2010.
http://en.wikipedia.org/wiki/eating—disorder, last accessed on Jun. 10, 2010.
http://en.wikipedia.org/wiki/sexual—dysfunction, last accessed on Jun. 10, 2010.
http://en.wikipedia.org/wiki/sleeping—disorder, last accessed on Jun. 10, 2010.
http://en.wikipedia.org/wiki/spinal—cord—trauma, last accessed on Jun. 10, 2010.
Borisy, et. al., Proceedings of the National Academy of Sciences of the United States of America, (2003), 100(13) 7977-7982.
Francois Giuliano et al., “The Pharmacological Treatment of Premature Ejaculation”; Journal Compilation, 2008; vol. 102, pp. 668-675.
Andrew W. Goddard et al., “Serotoninergic Mechanisms in the Treatment of Obsessive-Compulsive Disorder”; Drug Discovery Today, Apr. 2008, vol. 13, pp. 325-332.
Lucianne Groenink et al., “The Corticosterone-enhancing Effects of the 5-HT1Areceptor antagonist . . . ”, European Journal of Pharmacology, vol. 272, 1995, pp. 177-183.
Timo Heinrich et al., “Dual 5-HT1Aagonists and 5-HT Re-uptake Inhibitors by Combination of . . . ”, Bioorganic & Medicinal Chemistry, vol. 12, 2004, pp. 4843-4852.
5-HT1AAutoreceptors and the Mode of Action of Selective Serotonin Reuptake Inhibitors (SSRI), Behavioural Brain Research, vol. 73, 1996, pp. 281-283.
Sean L. Kitson, “5-Hydroxytryptamine (5-HT) Receptor Ligands”, Current Pharmaceutical Design, vol. 13, 2007, pp. 2621-2637.
Helmi L. Lutsep, “Repinotan, a 5-HT1A Agonist, in the Treatment of Acute Ischemic Stroke”, Current Drug Targets—CNS & Neurological Disorders, 2005, vol. 4, pp. 119-120.
Lisa Matzen et al., “5-HT Reuptake Inhibitors With 5-HT Antagonistic Activity . . . ”, Journal of Medicinal Chemistry, 2000, vol. 43 (6), pp. 1149-1157.
Gerd D. Bartoszyk et al., “EMD 281014, a New Selective Serotonin 5-HT2AReceptor Antagonist”, European Journal of Pharmacology, vol. 473, 2003, pp. 229-230.
Regis Bordet et al., “Effect of Pindolol on Onset of Action of Paroxetine . . . ”, Am J Psychiatry, 1998; vol. 155, pp. 1346-1351.
Alan D. Brown et al., “Designing Drugs for the Treatment of Female Sexual Dysfunction”, Drug Discovery Today, Sep. 2007, vol. 12, pp. 757-766.
Enza Lacivita et al., 5-HT1A, Receptor, an Old Target for New Therapeutic Agents >>, Current Topics in Medical Chemistry, 2008, vol. 8, pp. 1024-1034.
Luisa de Angelis, “5-HT2AAntagonists in Psychiatric Disorders”, Current Opinion in Investigational Drugs 2002, vol. 3(1), pp. 106-112.
Giuseppe di Giovanni et al., “Serotonin Involvement in the Basal Galglia Pathophysiology . . . ”, Current Medicinal Chemistry, 2006, vol. 13, pp. 3069-3081.
Laura J. Dreshfield et al., “Enhancement of Fluoxetine-Dependent Increase of Extracellular . . . ”, Neurochemical Research, 1996, vol. 21, No. 5, pp. 557-562.
Ray W. Fuller, “Uptake Inhibitors Increase Extracellular Serotonin Concentration Measured by Brain Microdyalysis”, Life Sciences, 1994, vol. 55, No. 3, pp. 163-167.
Patricia W. Nance, “Alpha Adrenergic and Serotonergic Agents in the Treatment of Spastic Hyertonia”, physical Medicine and Rehabilitation Clinics of North America, 2001, vol. 12, No. 4, pp. 889-905.
Ian A. Pullar et al., “In Vitro Activity of LY393558, an Inhibitor of the 5-Hydroxytryptamine Transporter . . . ”, European Journal of Pharmacology, 2001, vol. 432, pp. 9-17.
D.J. Sanger, “New Perspectives for the Treatment of Disorders of Sleep and Arousal”, Ann Pharm Fr, 2007, vol. 65, p. 268-274.
Kristine J. Steffen, “Emerging Drugs for Eating Disorder Treatment”, Expert Opin, Emeergfing Drugs, 2006, vol. 11, No. 2, pp. 315-336.
Raffaella Zanardi et al., “How Long Should Pindolol be Associated With Paroxetine . . . ”, Journal of Clinical Psychopharmacology, vol. 17, No. 6, pp. 446-450.
“Seroteonergic Mechanisms in Amyotrophic Lateral Sclerosis”, intern. J. Neuroscience, 2006, vol. 116, pp. 775-826.
L. Romero et al., “Two Actions are Better Than One: Avoding Self-Inhibiton . . . ”, International Clinical Psychopharmacology, 1996, vol. 11, pp. 1-8.

Affiliated with

Also associated with

Rating

Chromenoneindoles does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chromenoneindoles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chromenoneindoles will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2736840